The Qiagen-founded precision cancer technology provider agreed to an acquisition by Invitae sized at at least $325m in cash and shares currently valued at about $820m.

Vcanbio scored an exit as the precision cancer treatment and diagnostics developer went public in an upsized offering priced well above its range.

Ona Therapeutics is working on treatments for metastatic cancer and has collected series A funding from investors including Bpifrance.

Novartis is the second largest investor in the gene therapy developer, which has filed to go public less than a year after closing a $150m round.

The series C round consisted of $77m in equity funding and $25m in venture debt, with Kaiser Permanente among the participants.

Hartford Healthcare returned for a $50m series C round that will support the Stanford spinout in advancing potential treatments for severe liver and inflammatory bowel diseases.

Kaiser Permanente Ventures and Samsung Next invested in the digital mental health treatment developer through a series B round that will fund product development and commercialisation.

Engrail Therapeutics has completed a series A round led by Nan Fung Life Sciences as it targets a validated mechanism-based approach to nervous system treatments.

Axa Venture Partners was among the limited partners that have helped the deep tech-focused venture firm raise $59.4m for its second fund.

Optum Ventures co-led a series B round that took the chronic disease management platform's total funding to $50m.